Intravitreal Bevacizumab for Diabetic Retinopathy

Conditions

• Active Photocoagulated Diabetic Retinopathy
• Proliferative Diabetic Retinopathy
• Severe Nonproliferative

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• intravitreal bevacizumab — DRUG

Study Details

Background: to evaluate the 3-month efficacy of a single dose of intravitreal bevacizumab on the progression of severe non proliferative diabetic retinopathy, proliferative diabetic retinopathy and active photocoagulated diabetic proliferative by evaluation of ischemic areas and regression of retinal and disc neovasculrization. Methods: 40 patients were enrolled in a prospective, interventional study. Patients were treated with intravitreal bevacizumab 0.1ml (0.25mg). We evaluated visual acuity, neovascularization leakage points, capillary closure ischemic areas and macular edema by clinical examination and fluorescein angiography. A clinical examination was performed at baseline and days 1,14 and 30. Active leakage points were measured by fluorescein angiography at 30 days.

Key Dates

First listed

Jan 24, 2008

Start date

Dec 31, 2005

Status verified

May 2024

Completion

Jun 30, 2006

Study Design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT